EXC vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 21, 2026
EXC
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | EXC | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 13.9082 | 23.0415 | EXC |
| PEG Ratio | 2.2811 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 9.9% | 2.1% | EXC |
| Earnings Growth | -0.2% | -85.1% | EXC |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 45.4/100 | 58.2/100 | MRNA |
| Profit Margin | 11.0% | -141.4% | EXC |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
EXC
MarkdownPrice below a falling SMA50 (slope -2.6%), weak momentum, RSI 32
MRNA
MarkupPrice above SMA50, rising 50-day trend (49.6% over 20 days), RSI 63
Fundamentals Snapshot
| Metric | EXC | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.9 | -32.2 |
| Trailing P/E | 15.7 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.4% | -0.7% |
| Operating Margin | 0.2% | -5.6% |
| EPS | 2.72 | -8.66 |
| Dividend Yield | 0.04% | — |